ÂÜÀòÂÒÂ×

Mark Aurousseau, PhD has a diverse work experience. Mark began their career in 2006 as an Inhalation Toxicology Technician at Charles River Laboratories. In 2007, they became a Master's Student at AstraZeneca R&D Montreal. From 2008 to 2015, they were a Research Assistant at McGill University. From 2015 to 2017, they were a Postdoctoral Fellow at McGill University, where their research focused on the design and development of new fluorescence-based research tools. In 2017, they became a Research Scientist at The Montreal Neurological Institute, where their research focused on assay development in the context of neurodegenerative disease. Since 2016, they have been the Chief Scientific Officer at eNUVIO, a company that develops next-generation microfabricated devices for the life science research and drug discovery markets.

Mark Aurousseau, PhD, obtained their Bachelor's Degree in Physiology with a Minor in Pharmacology from McGill University in 2005. Mark then went on to obtain their Master's Degree in Biotechnology from McGill University's Macdonald Campus in 2008. Finally, they completed their Doctor of Philosophy (Ph.D.) in Pharmacology and Toxicology from McGill University in 2015.